Submitted by web@researchtop... on Wed, 11/25/2009 - 13:14
Studies on the Efficacy and Safety of Deferasirox for Iron Chelation in Patients with MDS: EPIC and US03
Gattermann N et al. Efficacy and safety of deferasirox (Exjade®) during 1 year of treatment in transfusion-dependent patients with myelodysplastic syndromes: Results from EPIC trial. Blood 2008;112;Abstract 633.
List AF et al. Iron chelation with deferasirox (Exjade®) improves iron burden in patients with myelodysplastic syndromes (MDS). Blood 2008;112;Abstract 634.